ublituximab
ublituximab: developed by 1 company · 13 clinical trials tracked.
ublituximab evidence translation
What we can confirm
13 tracked trials
What it means
What to watch
Prepared research question
How could ublituximab → TGTX affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence7 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (2)
| Company | Phase |
|---|---|
| TG THERAPEUTICS, INC. (TGTX) Schizophrenia; Multiple Sclerosis; Relapsing Multiple Sclero… | Phase 3 |
| TG THERAPEUTICS, INC. (TGTX) Schizophrenia; Multiple Sclerosis; Relapsing Multiple Sclero… | Phase 3 |
Clinical Trials (13)showing 10 most recent
A Phase 2, Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Treatment Following Induction With Efgartigimod Administration in Adults With Myasthenia Gravis
Primary endpoint: Time to Onset of a Clinical Worsening Event
Evaluating Safety and Efficacy of Ublituximab in Participants With Schizophrenia
Primary endpoint: Percentage of Participants with at Least 20% Reduction From Baseline in PANSS Total Score
Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)
Primary endpoint: Part A: Area Under the Curve From Week 0 to 24 (AUC0-W24) of Ublituximab
Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis
Primary endpoint: Evaluation of the effect of ublituximab on macular hyperreflective foci (HRF) in MS.
Study of Ublituximab in Early, Active, Autoantibody-Positive, IMMune-MedIated NecroTizing Myopathy (AIM01)
Primary endpoint: The primary endpoint is the Total Improvement Score (TIS) at Week 24 reflecting the change from baseline
A Phase 2, Multicenter, Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector Device Versus Syringe in Patients With Multiple Sclerosis
Primary endpoint: Part 2: Area under the curve (AUC) at Steady State [AUCss] of Ublituximab
A Pilot Study of Ublituximab in People With MS Experiencing Wearing Off Phenomena While Receiving Treatment With Ocrelizumab
Primary endpoint: Proportion of Patients with Wearing-Off
Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
Primary endpoint: Change in plasma neurofilament light chain
A Phase 3, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab Versus Intravenous Ublituximab in Patients With Multiple Sclerosis
Primary endpoint: Area Under the Curve From Week 0 to Week 24 (AUC0-W24) of Ublituximab
Evaluating Safety, Efficacy and Pharmacokinetics of a Modified Regimen of Ublituximab (ENHANCE )
Primary endpoint: Part A and Part C: Percentage of Participants With no Change or Reduction in Number of T1 Gd-Enhancing Lesions From Baseline to Week 48
Frequently asked questions
Who is developing ublituximab?
ublituximab is being developed by TG THERAPEUTICS, INC..
How many clinical trials involve ublituximab?
BioSniper tracks 13 clinical trials involving ublituximab.